Programming CD8+ T cells for effective immunotherapy

Current Opinion in Immunology

Volumn 18, Issue 3, 2006, Pages 363-370

  Hinrichs, Christian S ^a   Gattinoni, Luca ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE RECEPTOR; T LYMPHOCYTE RECEPTOR;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL FUNCTION; CELL LINEAGE; CELLULAR IMMUNITY; EFFECTOR CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL;

EID: 33646149184     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.03.009     Document Type: Review

References (71)

1. + T cells undergo death via TNF-related apoptosis-inducing ligand (TRAIL)-mediated signaling after re-challenge with antigen.
2. + T lymphocyte responses. Nat Immunol 4 (2003) 361-365
3. Masopust D., Kaech S.M., Wherry E.J., and Ahmed R. The role of programming in memory T-cell development. Curr Opin Immunol 16 (2004) 217-225
4. Wilson C.B., Makar K.W., Shnyreva M., and Fitzpatrick D.R. DNA methylation and the expanding epigenetics of T cell lineage commitment. Semin Immunol 17 (2005) 105-119
5. Wilson C.B., and Merkenschlager M. Chromatin structure and gene regulation in T cell development and function. Curr Opin Immunol 18 (2006) 143-151
6. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., von Andrian U.H., and Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 (2003) 225-234
7. + T-cell function in vivo.
8. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102 (2005) 9571-9576
9. + T cells in vitro and in vivo based on expression of the molecules CD27 and CD28. Furthermore the loss of proliferative capacity associated with this process is firmly established in this work.
10. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., and Robbins P.F. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175 (2005) 7046-7052
11. Roberts A.D., Ely K.H., and Woodland D.L. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 202 (2005) 123-133
12. Sallusto F., Geginat J., and Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22 (2004) 745-763
13. Kaech S.M., Hemby S., Kersh E., and Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111 (2002) 837-851
14. Appay V., and Rowland-Jones S.L. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin Immunol 16 (2004) 205-212
15. Lanzavecchia A., and Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 17 (2005) 326-332
16. + T-cell responses. Curr Opin Immunol 16 (2004) 259-263
17. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708-712
18. + memory cells in humans defined by HLA and CC chemokine ligand 19 tetramers. J Immunol 170 (2003) 2461-2468
19. - memory T cells do not differ in immediate effector cell function. J Immunol 169 (2002) 638-641
20. Chen G., Shankar P., Lange C., Valdez H., Skolnik P.R., Wu L., Manjunath N., and Lieberman J. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 98 (2001) 156-164
21. Ellefsen K., Harari A., Champagne P., Bart P.A., Sekaly R.P., and Pantaleo G. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol 32 (2002) 3756-3764
22. EFF.
23. + central and effector memory T cell subsets are largely distinct. Immunity 18 (2003) 193-204
24. Bouneaud C., Garcia Z., Kourilsky P., and Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 201 (2005) 579-590
25. + T cells whereas low precursor frequency leads to an effector memory phenotype. Because competition for antigen by T cells might limit antigenic stimulation, the author's findings might instead stem from differences in the strength and duration of TCR signaling.
26. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8 (2002) 379-385
27. Willinger T., Freeman T., Hasegawa H., McMichael A.J., and Callan M.F. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol 175 (2005) 5895-5903
28. Fearon D.T., Manders P., and Wagner S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 293 (2001) 248-250
29. Sacre K., Carcelain G., Cassoux N., Fillet A.M., Costagliola D., Vittecoq D., Salmon D., Amoura Z., Katlama C., and Autran B. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201 (2005) 1999-2010
30. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25 (2002) 243-251
31. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99 (2002) 16168-16173
32. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
33. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell Jr. D.J., and Rosenberg S.A. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173 (2004) 7125-7130
34. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105 (2005) 241-250
35. Wherry E.J., Blattman J.N., and Ahmed R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 79 (2005) 8960-8968
36. Bondanza A., Valtolina V., Magnani Z., Ponzoni M., Fleischhauer K., Bonyhadi M., Traversari C., Sanvito F., Toma S., Radrizzani M., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107 (2006) 1828-1836
37. Hatton R.D., and Weaver C.T. Immunology. T-bet or not T-bet. Science 302 (2003) 993-994
38. Messi M., Giacchetto I., Nagata K., Lanzavecchia A., Natoli G., and Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4 (2003) 78-86
39. Zhou W., Chang S., and Aune T.M. Long-range histone acetylation of the Ifng gene is an essential feature of T cell differentiation. Proc Natl Acad Sci USA 101 (2004) 2440-2445
40. Avni O., Lee D., Macian F., Szabo S.J., Glimcher L.H., and Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 3 (2002) 643-651
41. Sundrud M.S., Grill S.M., Ni D., Nagata K., Alkan S.S., Subramaniam A., and Unutmaz D. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J Immunol 171 (2003) 3542-3549
42. + T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6 (2005) 1236-1244. This publication offers new insight into how the transcriptional master regulators T-bet and Eomes redundantly determine not only effector lineage commitment but also survival of committed lineages. Mice that have compound mutations in the genes that encode these transcription factors were nearly devoid of several IL-15-dependent lineages. T-bet and Eomes were found to be responsible for enhanced expression of the IL-2/IL-15 receptor β-chain.
43. + T cells. Nat Immunol 3 (2002) 558-563
44. + T cells. J Immunol 173 (2004) 883-891
45. + T lymphocytes. Proc Natl Acad Sci USA 102 (2005) 7418-7425
46. Reya T., and Clevers H. Wnt signalling in stem cells and cancer. Nature 434 (2005) 843-850
47. Willinger T., Freeman T., Herbert M., Hasegawa H., McMichael A.J., and Callan M.F. Human naïve CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T Cell Factor-1) following antigen encounter in vitro and in vivo. J Immunol 176 (2006) 1439-1446
48. Schilham M.W., Wilson A., Moerer P., Benaissa-Trouw B.J., Cumano A., and Clevers H.C. Critical involvement of Tcf-1 in expansion of thymocytes. J Immunol 161 (1998) 3984-3991
49. + T-cell memory formation.
50. + T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2 (2001) 415-422
51. van Stipdonk M.J., Lemmens E.E., and Schoenberger S.P. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2 (2001) 423-429
52. Hollander G.A., Zuklys S., Morel C., Mizoguchi E., Mobisson K., Simpson S., Terhorst C., Wishart W., Golan D.E., Bhan A.K., et al. Monoallelic expression of the interleukin-2 locus. Science 279 (1998) 2118-2121
53. Naramura M., Hu R.J., and Gu H. Mice with a fluorescent marker for interleukin 2 gene activation. Immunity 9 (1998) 209-216
54. Thomas R.M., Gao L., and Wells A.D. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol 174 (2005) 4639-4646
55. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
56. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
57. Weiner H.L. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol Rev 182 (2001) 207-214
58. Battaglia M., Gregori S., Bacchetta R., and Roncarolo M.-G. Tr1 cells: from discovery to their clinical application. Semin Immunol 18 (2006) 120-127
59. Cerwenka A., Carter L.L., Reome J.B., Swain S.L., and Dutton R.W. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J Immunol 161 (1998) 97-105
60. + T cells secreting Th1 or Th2 cytokines. Immunity 2 (1995) 271-279
61. Schluns K.S., and Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3 (2003) 269-279
62. + T cells. Proc Natl Acad Sci USA 101 (2004) 1969-1974
63. Manjunath N., Shankar P., Wan J., Weninger W., Crowley M.A., Hieshima K., Springer T.A., Fan X., Shen H., Lieberman J., et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 108 (2001) 871-878
64. + T cells in mouse and human.
65. •].
66. Ahmadzadeh M., and Rosenberg S.A. TGF-β 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174 (2005) 5215-5223
67. + T cell primary responses and inhibition of secondary responses. J Immunol 174 (2005) 5382-5389
68. Owaki T., Asakawa M., Morishima N., Hata K., Fukai F., Matsui M., Mizuguchi J., and Yoshimoto T. A role for IL-27 in early regulation of Th1 differentiation. J Immunol 175 (2005) 2191-2200
69. + T cell generation with enhanced granzyme B expression by IL-27. J Immunol 175 (2005) 1686-1693
70. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., and Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687. This work shows that it might be possible in one model (lymphocytic choriomeningitis virus) to reverse T-cell 'exhaustion' by blocking negative regulatory signals sent by way of PD-1. These findings vividly illustrate the kind of maneuver that might enable vaccines and immunotherapies for cancer and chronic infectious disease to overcome effector exhaustion associated with terminal differentiation.
71. Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R., Boss J.M., and Wade P.A. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119 (2004) 75-86. This study describes how the manipulation of key transcriptional factors might be used to reprogram the lymphocyte fate. The authors were able to de-differentiate plasma cells into less differentiated B cells by forcing the expression of BCL-6 and MTA-3.